Filing Flows › Zevra Therapeutics (ZVRA) › Q2 2026
Zevra Therapeutics (ZVRA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Zevra Therapeutics (ZVRA) reported revenue of $39.7M for the second quarter 2026 (Q2 2026), +53% from a year earlier and +10% from the quarter before. Operating margin was 42.3%, net earnings $8.8M (22.1% of revenue).
Zevra Therapeutics, Q2 2026: revenue $39.7M (+53% year over year), operating margin 42.3%, net earnings $8.8M, operating cash flow $17.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $39.7M | +10% | +53% |
| Operating profit | $16.8M | -68% | — |
| Net earnings | $8.8M | -77% | -88% |
| Operating cash flow | $17.0M | +177% | — |
| Free cash flow | $16.8M | +175% | — |
What changed
Revenue was $39.7M in Q2 2026, up 53% year over year and up 10% from the previous quarter.
Operating profit was $16.8M, a 42.3% margin (up 316.8 points year over year). Total costs fell 76% while revenue rose 53%. The fastest-growing cost line was Research & development (+31%). Net earnings were $8.8M, down 88% year over year. The effective tax rate was 31.6%.
Operating cash flow was $17.0M, 195% of net earnings. Non-cash charges added back $364K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items added $4.9M. Capital expenditures of $217K left free cash flow of $16.8M.
Questions
What was Zevra Therapeutics' revenue in the second quarter 2026?
Zevra Therapeutics (ZVRA) reported revenue of $39.7M for the second quarter 2026 (Q2 2026), +53% from a year earlier and +10% from the quarter before.
Was Zevra Therapeutics profitable in the second quarter 2026?
Operating profit was $16.8M (42.3% of revenue) and net earnings $8.8M.
Source: Zevra Therapeutics 10-Q on SEC EDGAR.